Interim report of the UKCLL02 Trial: a phase II study of subcutaneous alemtuzumab plus fludarabine in patients with fludarabine refractory CLL (on behalf of the NCRI CLL Trials Sub-Group)

被引：0
|
作者：
Sayala, HA
Moreton, P
Jones, RA
Rawstron, AC
O'Connor, SJ
Evans, P
Carter, A
Dearden, C
Matutes, E
Pettitt, AR
Kennedy, DB
Hillmen, P
机构：
[1] Leeds Gen Infirm, HMDS, Leeds, W Yorkshire, England
[2] Royal Liverpool Univ Hosp, Dept Haematol, Liverpool, Merseyside, England
[3] Inst Canc Res, Haematooncol Dept, London SW3 6JB, England
[4] Leicester Royal Infirm, Dept Haematol, Leicester, Leics, England
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2006年 / 133卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：3 / 3
页数：1
相关论文
共 50 条
  • [21] An open-label phase II study to investigate the safety and efficacy of rituximab plus chlorambucil in previously untreated patients with CD20-positive B-cell chronic lymphocytic leukaemia (CLL): On behalf of the NCRI CLL sub-group
    Hillmen, P.
    Gribben, J. G.
    Follows, G. A.
    Milligan, D. W.
    Sayala, H. A.
    Moreton, P.
    Oscier, D.
    Dearden, C. E.
    Kennedy, D. B.
    Pettitt, A. R.
    Nathwani, A.
    Cohen, D.
    Gregory, W. M.
    Rawstron, A. C.
    Hayward, C. R. W.
    Pocock, C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2010, 149 : 2 - 2
  • [22] Concomitant treatment of patients with relapsed/refractory CLL using a combination of fludarabine and alemtuzumab is highly effective: Final results of a phase-II study.
    Engert, A
    Elter, T
    Borchmann, P
    Schulz, H
    Reiser, M
    Trelle, S
    Staib, P
    Schinkoethe, T
    Hallek, M
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 574S - 574S
  • [23] Rituximab Maintenance In Patients with Chronic Lymphocytic Leukemia (CLL) After Upfront Treatment with Rituximab Plus Fludarabine, Cyclophosphamide, and Mitoxantrone (R-FCM): Final Results of a Multicenter Phase II Trial On Behalf of the Spanish CLL Study Group (GELLC)
    Bosch, Francesc
    Abrisqueta, Pau
    Villamor, Neus
    Jose Terol, Maria
    Gonzalez-Barca, Eva
    Gonzalez, Marcos
    Ferra, Christelle
    Abella, Eugenia
    Delgado, Julio
    Garcia-Marco, Jose A.
    Gonzalez, Yolanda
    Carbonell, Felix
    Ferrer, Secundino
    Monzo, Encarna
    Jarque, Isidro
    Muntanola, Ana
    Constants, Mireia
    Escoda, Lourdes
    Montserrat, Emili
    BLOOD, 2011, 118 (21) : 136 - 137
  • [24] More severe infectious complications in CLL patients treated with fludarabine, cyclophosphamide, rituximab (FCR) in comparison to bendamustin plus rituximab (BR): Results of the interim-analysis of the CLL10 trial of the German CLL Study Group
    Langerbeins, P.
    Busch, R.
    Schweighofer, C. D.
    Mueller, C.
    Fischer, K.
    Fink, A. -M.
    Cramer, P.
    Faetkenheuer, G.
    Hartmann, P.
    Stilgenbauer, S.
    Boettcher, S.
    Wendtner, C. -M.
    Hallek, M.
    Eichhorst, B.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 185 - 185
  • [25] Results of a phase II trial of a fludarabine with concomitant application of alemtuzumab in a four-weekly schedule (FluCam) in patients with relapsed CLL.: 2nd Interim analysis
    Elter, T
    Borchmann, P
    Schulz, H
    Reiser, M
    Trelle, S
    Staib, P
    Schinköthe, T
    Engert, A
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 605S - 605S
  • [26] Rituximab Maintenance Treatment After Combined Fludarabine, Cyclophosphamide and Rituximab In Previously Untreated Patients with Progressive B-Cell Chronic Lymphocytic Leukemia (CLL): Interim Analysis of An Ongoing Phase II Multicenter Trial On Behalf of the Spanish CLL Study Group (GELLC)
    Garcia-Marco, Jose A.
    Lopez-Jimenez, Javier
    Ferrer, Secundino
    Giraldo, Pilar
    Gonzalez-Barca, Eva
    Navarro, Belen
    Conde, Eulogio
    Gonzalez, Marcos
    Guzman, Jose L.
    Perez, Ernesto
    De la Serna, Javier
    Osma, Mar
    Deben, Guillermo
    Monzo, Encarna
    de Paz, Raquel
    Angeles Ruiz, M.
    Penalver, Francisco-Javier
    Jarque, Isidro
    Banas, Helena
    Carmen Fernandez, M.
    Martinez, Rafael
    Burgaleta, Carmen
    Perez de Oteiza, Jaime
    Angeles Andreu, M.
    Carral, Ana
    Fuentes, Inmaculada
    Donato, Eva
    Leon, Paola
    Carbonell, Felix
    Garcia-Vela, Jose A.
    BLOOD, 2010, 116 (21) : 1016 - 1016
  • [27] Fludarabine, Cyclophosphamide, and Alemtuzumab (FCC) In Relapsed/Refractory Patients with B-Cell Chronic Lymphocytic Leukemia (CLL): Final Report of the Italian Study
    Montillo, Marco
    Tedeschi, Alessandra
    Ricci, Francesca
    Zaccaria, Alfonso
    Crugnola, Monica
    Spriano, Mauro
    Spedini, PierAngelo
    Ilariucci, Fiorella
    Uziel, Lilj
    Attolico, Immacolata
    De Blasio, Angelo
    Vismara, Eleonora
    Morra, Enrica
    Petrizzi, Valeria Belsito
    BLOOD, 2010, 116 (21) : 595 - 596
  • [28] Fludarabine plus cyclophosphamide induces better response rates and progression-free survival across all age and risk groups in the LRF CLL4 trial (on behalf of the UKNCRI CLL Trials Group)
    Catovsky, D
    Richards, S
    Dearden, C
    Matutes, E
    Dyer, M
    Hillmen, P
    BRITISH JOURNAL OF HAEMATOLOGY, 2006, 133 : 2 - 2
  • [29] Chemoimmuno-Therapy with Fludarabine, Cyclophosphamide and Alemtuzumab (FC-Cam) in Patients with Relapsed or Genetic High-Risk CLL: Final Analysis of the CLL2L Trial of the German CLL Study Group
    Elter, Thomas
    James, Rojin
    Stilgenbauer, Stephan
    Boettcher, Sebastian
    Ritgen, Matthias
    Doehner, Hartmut
    Hallek, Michael
    Engert, Andreas
    BLOOD, 2009, 114 (22) : 92 - 92
  • [30] Interim Analysis of EFC6663, a Multicenter Phase 2 Study of Alvocidib (flavopiridol), Demonstrates Clinical Responses Among Patients with Fludarabine Refractory CLL
    Lanasa, Mark C.
    Andritsos, Leslie
    Brown, Jennifer R.
    Gabrilove, Janice
    Caligaris-Cappio, Federico
    Larson, Richard
    Kipps, Thomas J.
    Leblond, Veronique
    Milligan, Donald
    Janssens, Ann
    Heerema, Nyla A.
    Stilgenbauer, Stephan
    Byrd, John C.
    Grever, Michael R.
    BLOOD, 2010, 116 (21) : 32 - 33
12345